Portola Pharmaceuticals, Inc.
| Article | Date | Source |
|---|
| Portola Announces Its Factor Xa Inhibitor Antidote PRT4445 Produces Rapid, Sustained and Dose-Related Reversal of the Anticoagulant Activity of Eliquis(R) in Phase 2 Study | May 08, 2013 | Marketwire - Pharma and Biotech |
| Portola sets IPO stock at $13 to $16 | May 07, 2013 | Health News - BizJournals.com |
| Portola Pharmaceutical sets targets for $127M IPO | May 07, 2013 | Health News - BizJournals.com |
| Portola rolls out $115M IPO plan as more biotech outfits go public | April 13, 2013 | FierceBiotech |
| Portola Files Registration Statement for Proposed Initial Public Offering | April 12, 2013 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals seeks $115 million IPO | April 12, 2013 | Health News - BizJournals.com |
| Bayer AG, Johnson & Johnson Sign Partner Deal With Portola Pharmaceuticals, Inc. for Xarelto Antidote | February 05, 2013 | BioSpace |
| Portola Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 2 Study of Universal Factor Xa Inhibitor Antidote, PRT4445, and XARELTO(R) | February 05, 2013 | Marketwire - Pharma and Biotech |
| Portola and Lee's Pharmaceutical Enter Into Agreement to Expand Phase 3 APEX Study of Betrixaban Into China | January 29, 2013 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals, Inc. Initiates Global Pivotal Phase 3 Study of Factor Xa Inhibitor Betrixaban | March 30, 2012 | BioSpace - Breaking News |
| Portola Initiates Global Pivotal Phase 3 Study of Factor Xa Inhibitor Betrixaban | March 30, 2012 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals, Inc.: Series E $89M | January 31, 2012 | OnBioVC |
| Portola Brings in Cash to Advance Anticoagulant | November 22, 2011 | Burrill Report |
| Going it alone, Portola raises $89M to work on blood thinner, antidote | November 21, 2011 | Health News - BizJournals.com |
| Portola raises $89M for late-stage betrixaban study | November 21, 2011 | FierceBiotech |
| Portola Pharmaceuticals, Inc. Announces Completion of $89 Million Financing | November 21, 2011 | BioSpace - Breaking News |
| Portola Pharma raises $89M in preferred stock financing | November 21, 2011 | Health News - BizJournals.com |
| Portola Pharmaceuticals Announces Completion of $89 Million Financing | November 21, 2011 | Marketwire - Pharma and Biotech |
| Biogen Idec, Portola Pharma form potential $554M deal | October 27, 2011 | Health News - BizJournals.com |
| Drug deal gives Biogen a stake in Portola Pharmaceuticals | October 27, 2011 | Health News - BizJournals.com |
| Biogen Idec, Inc. (Massachusetts), Portola Pharmaceuticals, Inc. Strike $553 Million Deal for Oral Syk Inhibitor | October 27, 2011 | BioSpace |
| Resumen: Biogen Idec y Portola Pharmaceuticals anuncian colaboración global para el programa Syk oral para el tratamiento de enfermedades autoinmunes e inflamatorias | October 27, 2011 | Pharma News - Business Wire |
| Samenvatting: Biogen Idec en Portola Pharmaceuticals kondigen internationale samenwerking aan voor oraal syk-remmerprogramma gericht op auto-immuunziekten en infectieziekten | October 27, 2011 | Pharma News - Business Wire |
| Biogen Idec, Inc. (Massachusetts), Portola Pharmaceuticals, Inc. Strikes $553 Million Deal for Oral Syk Inhibitor | October 27, 2011 | BioSpace |
| Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs | October 27, 2011 | Xconomy Life Sciences |
| Biogen partners with Portola in $553M autoimmune drug pact | October 27, 2011 | FierceBiotech |
| Biogen partners with Portola in $553M autoimmune drug development pact | October 27, 2011 | FierceBiotech |
| Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases | October 27, 2011 | Pharma News - Business Wire |
| Riassunto: Biogen Idec e Portola Pharmaceuticals hanno annunciato una collaborazione globale per Oral Syk, il programma inibitore specifico per le malattie autoimmuni e infiammatorie | October 27, 2011 | Pharma News - Business Wire |
| Biogen Idec et Portola Pharmaceuticals annoncent une collaboration mondiale dans le cadre d’un programme d’inhibiteur oral de la kinase Syk ciblant les maladies auto-immunes et inflammatoires | October 27, 2011 | Pharma News - Business Wire |
| Biogen Idec und Portola Pharmaceuticals verkünden globale Zusammenarbeit beim Programm für den oral verabreichten SYK-Inhibitor bei Autoimmun- und Entzündungskrankheiten | October 27, 2011 | Pharma News - Business Wire |
| Portola Pharmaceuticals Announces Upcoming Oral Presentation of Factor Xa Inhibitor Antidote Data at ESC 2011 Congress | August 11, 2011 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Names Dr. Michael Kitt as Chief Medical Officer | July 18, 2011 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors | April 12, 2011 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Announces Initiation of Phase 1 Multiple Ascending Dose Trial of Oral Syk-Specific Inhibitor | March 31, 2011 | Marketwire - Pharma and Biotech |
| Portola pushing on after Merck pullout | March 25, 2011 | Health News - BizJournals.com |
| SV Feels Lonely at the Top, Canaan Finds Biotech Groove, Portola Gets Drug Back, & More in Bay Area Life Sciences News | March 25, 2011 | Xconomy Life Sciences |
| Scrappy Portola ready for new fight on blood thinner | March 24, 2011 | Health News - BizJournals.com |
| Portola Pharmaceuticals, Inc. to Regain Global Rights for Investigational Medicine Betrixaban from Merck & Co., Inc.; Breaks $470 Million Pact Made in 2009 | March 24, 2011 | BioSpace |
| Portola Pharmaceuticals, Inc. to Regain Global Rights for Investigational Medicine Betrixaban from Merck & Co., Inc. | March 24, 2011 | BioSpace |
| Portola Gets Drug Back From Merck | March 24, 2011 | Xconomy Life Sciences |
| Portola vows to go it alone after Merck spurns cardio drug pact | March 24, 2011 | FierceBiotech |
| Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck | March 24, 2011 | Pharma News - Business Wire |
| Accumetrics, Inc. Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc. | March 02, 2011 | BioSpace - Breaking News |
| Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc. | March 02, 2011 | Pharma News - PR Newswire |
| Portola Pharmaceuticals Appoints John T. Curnutte, M.D., Ph.D., to Head R&D | January 24, 2011 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Announces Presentation at J.P. Morgan's 29th Annual Healthcare Conference | January 05, 2011 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting | December 04, 2010 | Pharma News - PR Newswire |
| Portola Pharmaceuticals Announces Investigational Universal Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity of Factor Xa Inhibitors | November 15, 2010 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals, Inc. Appoints Jean-Jacques Bienaime to Board of Directors | September 23, 2010 | Biotechnology - Moreover |
| Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors | September 23, 2010 | Marketwire - Pharma and Biotech |
| Ex-Portola Pharma boss to head Third Rock's new SF office | September 13, 2010 | Health News - BizJournals.com |
| Novartis taking Portola blood thinner into Phase III | August 30, 2010 | Health News - BizJournals.com |
| Portola Pharmaceuticals, Inc. Announces That Phase 2 INNOVATE-PCI Trial With Elinogrel Achieved Objectives; Novartis AG to Start Final-Stage Test of Blood Thinner | August 30, 2010 | BioSpace |
| Portola Pharmaceuticals Announces That Phase 2 INNOVATE-PCI Trial With Elinogrel Achieved Objectives | August 30, 2010 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Announces Presentation of New Pharmacodynamic Data From Phase 2 Trial of Investigational Factor Xa Inhibitor, Betrixaban | August 29, 2010 | Marketwire - Pharma and Biotech |
| Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications | March 23, 2010 | Pharma News - PR Newswire |
| Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding... | March 16, 2010 | Pharma News - PharmiWeb |
| Merck & Co., Inc., Portola Pharmaceuticals, Inc. Blood Thinner Appears Safe, Effective-Study | March 15, 2010 | BioSpace |
| Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation | March 15, 2010 | Pharma News - Business Wire |
| Portola CEO shifts to chairman, COO promoted | March 11, 2010 | Health News - BizJournals.com |
| Portola Pharmaceuticals, Inc.'s Announces CEO, M.D. to Retire | March 11, 2010 | BioSpace - Breaking News |
| Portola Pharmaceuticals CEO to retire | March 11, 2010 | Health News - BizJournals.com |
| Portola Pharmaceuticals Announces Senior Management and Board Changes | March 11, 2010 | Medical Pharma - PR Newswire |
| Portola Pharmaceuticals, Inc. Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session | February 10, 2010 | BioSpace - Breaking News |
| Portola Pharmaceuticals, Inc. Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session | February 10, 2010 | BioSpace |
| Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session | February 10, 2010 | Pharma News - PR Newswire |
